scholarly journals Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin)

2006 ◽  
Vol 91 (5) ◽  
pp. 602-604 ◽  
Author(s):  
S K Gibran ◽  
A Sachdev ◽  
T Stappler ◽  
R Newsome ◽  
D Wong ◽  
...  
Keyword(s):  
Intravitreal Bevacizumab ◽  
Histological Findings ◽  
Choroidal Neovascular Membrane ◽  
Macular Translocation ◽  
Bevacizumab Treatment ◽  
Previously Treated

INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Retina ◽  
2006 ◽  
Vol 26 (4) ◽  
pp. 383-390 ◽  
Author(s):  
RICHARD F. SPAIDE ◽  
KETAN LAUD ◽  
HOWARD F. FINE ◽  
JAMES M. KLANCNIK ◽  
CATHERINE B. MEYERLE ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Choroidal Neovascularization ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Bevacizumab Treatment

Correlation of response to intravitreal bevacizumab treatment between the first and second treated eyes in diabetic macular edema

2021 ◽  
pp. 112067212110596
Author(s):  
Nadav Levinger ◽  
Liran Tiosano ◽  
Elishai Assayag ◽  
Rivkah Lender ◽  
Tomer Batash ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Thickness Reduction ◽  
Bevacizumab Treatment ◽  
Central Subfield Thickness ◽  
Bilateral Diabetic Macular Edema ◽  
The Mean ◽  
Selection Of

Purpose To evaluate whether outcome of bevacizumab treatment in the first treated eye can guide the selection of compound for the second treated eye in patients with bilateral diabetic macular edema. Methods Demographic, clinical, and optical coherence tomography data were retrospectively collected from consecutive patients who underwent bevacizumab therapy for bilateral diabetic macular edema. Change in central subfield thickness and visual acuity were evaluated and compared between the first treated eye and second treated eye. Results A total of 66 eyes of 33 patients were included in the study. The mean ± SD follow-up time was 13 ± 5 months. The mean ± SD central subfield thickness at baseline was 464 ± 30 μm in the first treated eye and 461 ± 29 μm in the second treated eye ( p = 0.91). Final central subfield thickness was reduced to 392 ± 27 μm in the first treated eye ( p = 0.01 compared with baseline) and 416 ± 25 μm in the second treated eye ( p = 0.03 compared with baseline). Using ≥5% or ≥10% reduction of central subfield thickness as diagnostic criteria to predict similar magnitude of thickness reduction in the first treated eye yielded a positive and negative predictive value ranging from 46% to 81%, and sensitivity and specificity ranging from 54% to 84%. Regression models did not show correlation between central subfield thickness reduction in first treated eye and the second treated eye at the end of follow-up. Conclusions Bevacizumab therapy reduced macular thickness in both eyes in bilateral diabetic macular edema. Treatment outcome of the first treated eye could not predict the outcome of the second treated eye. Particularly, failure to reduce central subfield thickness in the first treated eye does not preclude a favorable response to bevacizumab therapy in the second eye.

scholarly journals Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage

2018 ◽  
Vol 2018 ◽  
pp. 1-18 ◽  
Author(s):  
Jiao Lv ◽  
Miao-Miao Chen ◽  
Zhi-Hao Mu ◽  
Fang Wang ◽  
Zhong-Yi Qian ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Early Stage ◽  
Intravitreal Bevacizumab ◽  
Underlying Mechanism ◽  
Camp Response Element Binding ◽  
Adult Rats ◽  
Anti Vegf ◽  
Bevacizumab Treatment ◽  
Immunofluorescence Labeling ◽  
Bevacizumab Injection

Diabetic retinopathy is the leading cause of blindness, yet its treatment is very limited. Anti-VEGF drug has been widely applied in ocular disease, but its effects on diabetic retinopathy and the underlying mechanism have remained to be fully explored. To elucidate the role of anti-VEGF treatment, we sought to determine the effects of bevacizumab on diabetic neurovascular changes extending from the 3rd to 9th week with induced diabetes in adult rats. The retinal neurovascular changes included increased expression of VEGF, nNOS, iNOS, eNOS, and NO in the course of diabetes progression. In diabetic rats given bevacizumab injection, the ganglion cell loss and alterations of retinal thickness were ameliorated. In this connection, the immunofluorescence labeling of the above biomarkers was noticeably decreased. Along with this, Western blotting confirmed that bevacizumab treatment was associated with a decrease of VEGF, Flk-1, and cAMP response element binding and protein kinase C protein expression. The present results suggest that bevacizumab treatment in the early stage of the retinopathy may ameliorate the lesions of retinopathy, in which VEGF/Flk-1 signaling has been shown here to play an important role.

INTRAVITREAL BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH GOOD VISUAL ACUITY

Retina ◽  
2012 ◽  
Vol 32 (9) ◽  
pp. 1811-1820 ◽  
Author(s):  
Ruth Axer-Siegel ◽  
Elite Bor ◽  
Dan H. Bourla ◽  
Dov Weinberger ◽  
Karin Mimouni
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Good Visual Acuity ◽  
Age Related ◽  
Bevacizumab Treatment
Sign in / Sign up

Export Citation Format

Share Document